Results 141 to 150 of about 9,116 (260)

Differences in predominant collagen fiber orientation between dorsal and plantar trabecular bone tracts of adult mule deer calcanei suggest strain‐mode‐specific adaptation

open access: yesThe Anatomical Record, EarlyView.
Polarized microscopic images of the outer bone cortex (a and b) and deeper trabecular bone (c and d) of the deer calcaneus in thin cross‐sections. The brighter gray levels reflect more oblique‐to‐transverse collagen fibers in the compression/dorsal bone (a, c) and the darker gray levels reflect more longitudinal collagen in the tension/plantar bone (b,
John G. Skedros   +3 more
wiley   +1 more source

Key Challenges for Commercializing Perovskite–Silicon Tandem Solar Cells

open access: yesCarbon Energy, EarlyView.
This review discusses the scientific and technological challenges in advancing perovskite–silicon tandem solar cells (PSTSCs) from lab‐scale to commercial viability, focusing on long‐term stability, scalability, and economic feasibility. Key issues include intrinsic and extrinsic degradation factors, installation conditions, environmental impacts, and ...
Bilal Mehmood   +16 more
wiley   +1 more source

Reverse Engineering and Performance Evaluation of a Pump Impeller Fabricated With Additive Manufacturing

open access: yesChemie Ingenieur Technik, EarlyView.
This study explores the process chain for reverse engineering and additive manufacturing of a water pump impeller in a process plant. Key aspects include digital twin creation, CAD redesign, material certification, Hirtisation postprocessing, and performance testing. Insights highlight iterative design for improved precision and reliability.
Michael Stadler   +3 more
wiley   +1 more source

Population Pharmacokinetics and Exposure‐Response Analyses to Support Cofetuzumab Pelidotin (ABBV‐647) Dose Optimization in Non‐Small Cell Lung Cancer Patients

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Cofetuzumab pelidotin (Cofe‐P) is an anti‐protein tyrosine kinase 7 (PTK7) antibody‐drug conjugate (ADC) being investigated for the treatment of adults with PTK7‐expressing, recurrent non‐small cell lung cancer (NSCLC). The first‐in‐human (FIH) trial demonstrated tolerability of dosages ≤ 2.8 mg/kg once every 3 weeks (Q3W) and ≤ 3.2 mg/kg Q2W ...
Carla Biesdorf   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy